Patience pays off for Akero in MASH

Data from two different MASH populations shows long-term treatment with FGF21 drives deeper responses to therapy, including an unprecedented reversal of fibrosis in stage F4 compensated cirrhosis patients.

In the latest readout from South San Francisco-based Akero Therapeutics Inc. (NASDAQ:AKRO) — 96-week data from the Phase IIb SYMMETRY trial — efruxifermin achieved something other therapies for metabolic dysfunction-associated steatohepatitis (MASH) have not: statistical significance on reversing fibrosis in F4 MASH patients. ...